Salix Pharmaceuticals Announces Issuance Of MOVIPREP(R) Patent.Patent Protection Provided to September 1, 2024 RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SLXP) today announced the issuance of patent number US 7,169,381, entitled "Colon Cleaning Compositions and Methods," by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . This patent provides patent coverage until September 1, 2024 to the dry purgative purgative /pur·ga·tive/ (purg´it-iv) cathartic (1, 2). pur·ga·tive n. An agent used for purging the bowels. adj. Tending to cause evacuation of the bowels. composition containing PEG 3350, sodium sulfate sodium sulfate, chemical compound, Na2SO4. It is a white, orthorhombic crystalline compound at ordinary temperatures; above 100°C; it assumes a monoclinic structure, and above about 250°C; it assumes a hexagonal structure. , sodium chloride sodium chloride, NaCl, common salt. Properties Sodium chloride is readily soluble in water and insoluble or only slightly soluble in most other liquids. It forms small, transparent, colorless to white cubic crystals. , potassium chloride potassium chloride, chemical compound, KCl, a colorless or white, cubic, crystalline compound that closely resembles common salt (sodium chloride). It is soluble in water, alcohol, and alkalies. , sodium ascorbate a·scor·bate n. A salt of ascorbic acid. ascorbate a compound or derivative of ascorbic acid. See also sodium ascorbate. and ascorbic acid for oral solution, that we market in the United States under the trade name MOVIPREP([R]). Norgine has licensed rights, including this patent, to MOVIPREP in the United States to Salix Pharmaceuticals. The patent has composition of matter claims covering the MOVIPREP purgative that will be listed in the Orange Book. "The issuance of this patent is another important milestone in our ongoing effort to further strengthen the intellectual property position of our product portfolio," stated Carolyn Logan, President and Chief Executive Officer. "MOVIPREP is unique among the available purgatives in that it is the only PEG cleansing agent that incorporates ascorbic acid in its formulation. We believe this to be state-of-the-art technology creating a distinct advantage for this two-liter liquid PEG product in the growing bowel cleansing market, and we are pleased that this technology now is protected by extended patent coverage." Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina For other uses of this name, see Raleigh. Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. , develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 150-member gastroenterology specialty sales and marketing team. Salix markets COLAZAL([R]), XIFAXAN([R]), OSMOPREP[TM], VISICOL([R]), MOVIPREP([R]), AZASAN([R]), ANUSOL-HC([R]) and PROCTOCORT([R]). Balsalazide tablets, Granulated gran·u·late v. gran·u·lat·ed, gran·u·lat·ing, gran·u·lates v.tr. 1. To form into grains or granules. 2. To make rough and grainy. v.intr. Mesalamine, SANVAR([R]) (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development. For full prescribing information on Salix products, please visit www.salix.com. Salix trades on the NASDAQ National Market under the ticker symbol "SLXP". For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings. Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include intellectual property risks, management of rapid growth, risks of regulatory review and clinical trials, market acceptance for approved products, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion